Kezar Life Sciences Stock Price, News & Analysis

Kezar Life Sciences, Inc. (KZR) has completed enrollment in its Phase 2 PRESIDIO trial, evaluating KZR-616 for polymyositis (PM) and dermatomyositis (DM). The study, which involves 24 subjects, is a randomized, placebo-controlled trial designed to assess safety and efficacy over 32 weeks. Patients receive either KZR-616 or placebo, with top-line results expected in Q2 2022. KZR-616 has received Orphan Drug Designation from the FDA for PM and DM. This milestone is viewed as significant for advancing treatment options for these debilitating conditions.

Kezar Life Sciences, Inc. (KZR) reported its second quarter 2021 financial results, highlighting the completion of a Phase 1b study for KZR-616, which showed positive safety and efficacy in lupus nephritis patients. The company submitted an IND for KZR-261, aiming to initiate a Phase 1 trial for this anti-tumor agent. Q2 2021 net loss was $13 million, or $0.25 per share, compared to a loss of $9.5 million, or $0.22 per share, in Q2 2020. Cash reserves decreased from $140 million at year-end 2020 to $129 million, attributed to R&D expenses.

Kezar Life Sciences (Nasdaq: KZR) announced that Co-founder and Chief Scientific Officer, Christopher Kirk, will join the panel discussion on "Novel Targets for Autoimmune Diseases" at William Blair's Biotech Focus Conference on July 15, 2021, at 11:00 a.m. ET. The event will be webcast live, accessible through the Events & Presentations section of Kezar's website, with a replay available for 90 days post-conference. Kezar focuses on innovative treatments for autoimmune diseases and cancer, including KZR-616, currently in Phase 2 trials for lupus nephritis and other conditions.

Kezar Life Sciences (Nasdaq: KZR) has established a Clinical Advisory Committee to enhance clinical development strategies for its lead candidate, KZR-616, aimed at autoimmune diseases. This committee, comprising experts from various medical fields, will guide the company's therapeutic programs and patient-centric approaches. KZR-616 is a first-in-class selective immunoproteasome inhibitor currently undergoing Phase 2 trials for severe autoimmune conditions, demonstrating a favorable safety profile in earlier studies.

Kezar Life Sciences, Inc. (Nasdaq: KZR) announced results from the Phase 1b dose escalation of its MISSION study, focusing on KZR-616 for systemic lupus erythematosus (SLE). This first-in-class immunoproteasome inhibitor showed favorable safety and tolerability in 47 patients. The study observed significant improvement in disease activity scores, including reductions in anti-double-stranded DNA antibodies. Among patients with proliferative lupus nephritis, notable reductions in urine protein levels were recorded. The poster presented at EULAR highlights KZR-616's potential to transform treatment for SLE and lupus nephritis.

Kezar Life Sciences, Inc. (Nasdaq: KZR) has appointed Dr. Micki Klearman to its Board of Directors. Dr. Klearman, who brings over a decade of biopharmaceutical expertise, has significantly advanced treatments for autoimmune diseases such as rheumatoid arthritis and Giant Cell Arteritis during her tenure at Genentech/Roche. Her addition is expected to enhance Kezar's strategic direction as the company focuses on developing innovative therapies for immune-mediated diseases. This leadership change aims to leverage Dr. Klearman's experience to drive the company's research and clinical programs forward.

Kezar Life Sciences, a clinical-stage biotechnology firm focusing on immune-mediated and oncologic disorders, announced that CEO John Fowler will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 2:00 p.m. ET. The chat will be accessible via live webcast on the company's website, with a replay available for 90 days post-event. Kezar is developing innovative therapies, including KZR-616 for lupus nephritis and KZR-261, targeting cancer treatment.

Kezar Life Sciences (Nasdaq: KZR) will present a MISSION Phase 1b data update on June 2, 2021, at 4:30 p.m. ET during EULAR 2021. This event will showcase final data from a 25-week study assessing the safety and tolerability of KZR-616 in 47 patients with systemic lupus erythematosus. KZR-616, a first-in-class selective immunoproteasome inhibitor, has shown a favorable safety profile in earlier trials and is being evaluated for severe autoimmune diseases, with ongoing Phase 2 trials in lupus nephritis and other conditions.

Kezar Life Sciences (Nasdaq: KZR) announced its Q1 2021 financial results, reporting a net loss of $13 million, or $0.25 per share. Cash, cash equivalents, and marketable securities totaled $142.3 million. R&D expenses increased to $9.3 million, driven by the KZR-616 program. The company is advancing two clinical trials: MISSION for SLE and lupus nephritis, and PRESIDIO for dermatomyositis and polymyositis. KZR-261, a new protein secretion inhibitor, is on track for an IND submission by mid-2021. Interim data is expected later this year, showcasing ongoing development and commitment to growth.